Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FQHV2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $4,191
Award facts
- Contract value 100% obligated
- $4,190.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a $4,190.65 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for the supply of 68 mg Nexplanon implants, with an ultimate completion date of February 17, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The delivery order was issued under the company's existing Indefinite Delivery Contract (IDC) with the DLA, specifically the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was awarded on November 13, 2025, with a $499.999 billion ceiling value through December 31, 2036.
The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to provide the Department of Defense with comprehensive pharmaceutical supply chain support, including branded and generic prescription drugs, biologics, medical consumables, and specialty pharmaceutical products. This delivery order for contraceptive implants reflects DMS Pharmaceutical Group's role as a critical supplier within the federal military medical system, supporting recurring medical supply needs across Department of Defense healthcare facilities worldwide. The company has demonstrated substantial performance capabilities through numerous prior delivery orders and maintains no identified subcontractor relationships, positioning it as a direct supplier of pharmaceutical products to military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FQHV2?
SPE2DR26FQHV2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 26, 2026.
How much is contract SPE2DR26FQHV2 worth?
The government has obligated $4,191 on SPE2DR26FQHV2.
Is contract SPE2DR26FQHV2 an order under another contract?
Yes. SPE2DR26FQHV2 is a delivery order under SPE2DR25D9759, an indefinite delivery contract.
Was contract SPE2DR26FQHV2 competed?
The extent of competition for SPE2DR26FQHV2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award